An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy
What is the goal of the study?
This is a multicenter, open-label single-arm study in children age 1 month to less than 18 years with a pediatric epileptic syndrome (Cohort 1) or children age 1 month to less than 2 years with partial-onset seizures (POS) (Cohort 2). The study will consist of a Core Study and Extension Phase
Who can participate in the study?
Please contact the study team listed below to learn more.